Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

ClinicalTrials.gov ID: NCT00267254

Public ClinicalTrials.gov record NCT00267254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 27, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)

Study identification

NCT ID
NCT00267254
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
640 participants

Conditions and interventions

Interventions

  • simvastatin Drug
  • torcetrapib/atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2005
Primary completion
Not listed
Completion
Jul 31, 2006
Last update posted
Nov 20, 2007

2006

United States locations

U.S. sites
49
U.S. states
26
U.S. cities
49
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama
Pfizer Investigational Site Mobile Alabama
Pfizer Investigational Site Mesa Arizona
Pfizer Investigational Site Phoenix Arizona
Pfizer Investigational Site Tempe Arizona
Pfizer Investigational Site Little Rock Arkansas
Pfizer Investigational Site Los Angeles California
Pfizer Investigational Site San Diego California
Pfizer Investigational Site Santa Rosa California
Pfizer Investigational Site Boynton Beach Florida
Pfizer Investigational Site Melbourne Florida
Pfizer Investigational Site Merritt Island Florida
Pfizer Investigational Site Palm Bay Florida
Pfizer Investigational Site Safety Harbor Florida
Pfizer Investigational Site Tampa Florida
Pfizer Investigational Site Chicago Illinois
Pfizer Investigational Site Newton Kansas
Pfizer Investigational Site Topeka Kansas
Pfizer Investigational Site Wichita Kansas
Pfizer Investigational Site Madisonville Kentucky
Pfizer Investigational Site Boston Massachusetts
Pfizer Investigational Site Ann Arbor Michigan
Pfizer Investigational Site Canton Michigan
Pfizer Investigational Site Portage Michigan
Pfizer Investigational Site Troy Michigan
Pfizer Investigational Site Minneapolis Minnesota
Pfizer Investigational Site Kansas City Missouri
Pfizer Investigational Site St Louis Missouri
Pfizer Investigational Site Butte Montana
Pfizer Investigational Site Lincoln Nebraska
Pfizer Investigational Site Las Vegas Nevada
Pfizer Investigational Site Concord New Hampshire
Pfizer Investigational Site Trenton New Jersey
Pfizer Investigational Site Cooperstown New York
Pfizer Investigational Site East Syracuse New York
Pfizer Investigational Site Rochester New York
Pfizer Investigational Site Charlotte North Carolina
Pfizer Investigational Site Cincinnati Ohio
Pfizer Investigational Site Clinton South Carolina
Pfizer Investigational Site Cordova Tennessee
Pfizer Investigational Site Memphis Tennessee
Pfizer Investigational Site Milan Tennessee
Pfizer Investigational Site Dallas Texas
Pfizer Investigational Site Fort Worth Texas
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Payson Utah
Pfizer Investigational Site Salt Lake City Utah
Pfizer Investigational Site Norfolk Virginia
Pfizer Investigational Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00267254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2007 · Synced Apr 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00267254 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →